Could a diabetes drug duo protect transplanted kidneys?
NCT ID NCT05938712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing whether a 12-week combination of two common diabetes drugs—dapagliflozin (Farxiga) and semaglutide (Ozempic)—is safe and helpful for people who have received a kidney transplant. The 20 participants will take both drugs and be monitored for changes in kidney function and other health markers. The goal is to see if this combo can improve outcomes for transplant recipients, with or without type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (Farxiga) and semaglutide (Ozempic)
What this could lead to
If it works, this could point toward a new way to protect kidney function and manage weight or blood sugar in kidney transplant recipients.
What could go wrong
This is a very small, early pilot study with only 20 people, so results may not apply to everyone. The drugs also carry risks like dehydration or gastrointestinal side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••